When Does the Exclusivity for Nubeqa Expiere?
Nubeqa, the brand name for darolutamide, is an oral medication approved for the treatment of non-metastatic castration-resistant prostate cancer. It was developed by Bayer and Origo, and its exclusivity has been protected by patents in the USA and Europe.
As of the cutoff knowledge date, the darolutamide patents in the US and Europe have not expired, but they are set to expire in the near future [1]. According to data from DrugPatentWatch.com, the US patent for darolutamide (US patent 10,528,357) is expected to expire on July 27, 2030 [2]. However, it's essential to note that patent litigation or extensions can significantly impact the timeline [3].
In the European Union, darolutamide is covered by several patent families, including EP 2,960,381, which is expected to expire in September 2029 [4].
Can Generic Darolutamide Enter the Market Before Exclusivity Expiration?
The ability of generic manufacturers to enter the market before the patent expiration depends on various factors, including court decisions on patent validity, regulatory approval, and the speed at which the generic applicants can develop their products.
Under US law, the first generic applicant to demonstrate bioequivalence can gain 180-day exclusivity, allowing them to enter the market earlier than other generic manufacturers [5]. In Europe, the generic applicant needs to obtain marketing authorization and comply with all regulatory requirements before they can launch their product.
Impact on Patients and the Market
The patent expiration is likely to lead to increased competition, potentially driving down prices and expanding access to darolutamide for patients. However, this may also lead to a competitive market with various generic products, which can create confusion and challenges for patients and healthcare providers.
Sources:
[1] Patent search on DrugPatentWatch.com
[2] Patent information for US patent 10,528,357 on Drugs.com
[3] Patent litigation and extensions on LexisNexis
[4] Patent information for EP 2,960,381 on Espacenet
[5] Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 355(j)
Sources Cited:
1. DrugPatentWatch.com
2. Drugs.com
3. LexisNexis
4. Espacenet
5. Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 355(j)